Overview

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Etoposide
Etoposide phosphate